Where to Bet on the Next Generation of ADCs?
Wu Ni | Author You Yi | Editor In October, Hansoh Pharmaceutical licensed the overseas rights of its self-developed ADC drug targeting CDH17 to Roche. This gastrointestinal tumor target was also a hot topic at this year’s AACR conference, where over ten related ADC drugs were showcased, with nine from Chinese pharmaceutical companies. Industry insiders … Read more